Susanna Gatti High M.B.A. Net Worth

The estimated Net Worth of Susanna Gatti High is at least $13 Million dollars as of 11 September 2024. Ms High owns over 5,270 units of Dyne Therapeutics stock worth over $4,583,951 and over the last 8 years she sold DYN stock worth over $8,032,641. In addition, she makes $409,310 as Chief Operating Officer at Dyne Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms A DYN stock SEC Form 4 insiders trading

Ms has made over 23 trades of the Dyne Therapeutics stock since 2017, according to the Form 4 filled with the SEC. Most recently she sold 5,270 units of DYN stock worth $168,060 on 11 September 2024.

The largest trade she's ever made was selling 85,270 units of Dyne Therapeutics stock on 10 June 2024 worth over $2,583,681. On average, Ms trades about 7,790 units every 75 days since 2016. As of 11 September 2024 she still owns at least 140,612 units of Dyne Therapeutics stock.

You can see the complete history of Ms High stock trades at the bottom of the page.

Ms. Susanna Gatti High M.B.A. biography

Susanna Gatti High M.B.A. is the Chief Operating Officer at Dyne Therapeutics.

What is the salary of Ms A?

As the Chief Operating Officer of Dyne Therapeutics, the total compensation of Ms A at Dyne Therapeutics is $409,310. There are 4 executives at Dyne Therapeutics getting paid more, with Dewei Qiao having the highest compensation of $2,036,560.

How old is Ms A?

Ms A is 53, she's been the Chief Operating Officer of Dyne Therapeutics since . There are 7 older and 15 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.

What's Ms A's mailing address?

Susanna's mailing address filed with the SEC is C/O DYNE THERAPEUTICS, INC., 1560 TRAPELO ROAD, WALTHAM, MA, 02451.

Insiders trading at Dyne Therapeutics

Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes, and Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.

What does Dyne Therapeutics do?

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Complete history of Ms High stock trades at Bluebird bio Inc and Dyne Therapeutics

Dyne Therapeutics executives and stock owners

Dyne Therapeutics executives and other stock owners filed with the SEC include:

• Dewei Qiao,
  General Manager, Executive Director
• Shengyong Hu,
  Chief Financial Officer, Executive Director
• Joshua T. Brumm,
  CEO, Pres & Director
• Dr. Romesh Subramanian Ph.D.,
  Co-Founder & Advisor
• Susanna Gatti High M.B.A.,
  Chief Operating Officer
• Lanjun Xie,
  Non-Executive Independent Director
• Yuezhou Ou,
  Independent Non-Executive Director
• Jie Fu,
  Non-Executive Independent Director
• Shuguang Liu,
  Non-Executive Director
• Sunning Cheng,
  Non-Executive Director
• Jinjun Cao,
  Non-Executive Director
• Wing Yan Yuen,
  Company Secretary
• Shuguang Zhu,
  Deputy General Manager and Secretary of the Board
• Yong Zhang,
  Deputy General Manager
• Jianzhong Huang,
  Deputy General Manager
• Yan Cheng,
  Deputy General Manager
• Jun Zhi,
  Non-Executive Chairman of the Board
• Kate Mitchell,
  VP & Head of HR
• Richard William Scalzo M.B.A.,
  Sr. VP, Head of Fin. & Admin. and Treasurer
• Dr. Thomas-Christian Mix M.D., M.S.,
  Sr. VP of Clinical Devel.
• Richard William Scalzo,
  VP of Accounting & Admin. and Treasurer
• Daniel Wilson,
  VP & Head of Intellectual Property
• Debra Feldman,
  VP & Head of Regulatory Affairs
• Dr. Thomas-Christian Mix M.D.,
  Sr. VP of Clinical Devel.
• Dr. Oxana Beskrovnaya Ph.D.,
  Chief Scientific Officer
• Amy Reilly,
  VP of Corp. Communications & Investor Relations
• Richard Scalzo,
  VP of Accounting & Admin. and Treasurer
• Gene Kim,
  VP of Fin.
• Johanna Friedl Naderer,
  Chief Commercial Officer
• Lawrence Otto Klein,
  Director
• Capital Fund Iv Cooperatief...,
  10% owner
• Global Management Lp Logos,
  10% owner
• Dirk Kersten,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Romesh Subramanian,
  Chief Scientific Officer
• Susanna Gatti High,
  Chief Operating Officer
• Douglas Kerr,
  Chief Medical Officer
• Edward Hurwitz,
  
• Carlo Incerti,
  
• David Charles Lubner,
  
• Bioventures 2018, L.P.Mpm B...,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Capital Management, L.P.Kol...,
  
• Biomedical Innovation Maste...,
  10% owner
• Jason P Rhodes,
  
• Ventures, Llc Cure Duchenne,
  10% owner
• Manager Ii, Llc Vida Ventur...,
  
• Catherine Stehman Breen,
  
• Venture Opportunity Fund Ii...,
  
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Venture Fund Xi, L.P.Atlas ...,
  
• John Cox,
  CEO & President
• Wildon Farwell,
  Chief Medical Officer
• Jonathan Mc Neill,
  Chief Business Officer
• Richard William Scalzo,
  SVP, Head of Finance & Admin.
• Joshua T Brumm,
  CEO & President
• Oxana Beskrovnaya,
  Chief Scientific Officer
• Venture Opportunity Fund I,...,